© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
The AJMC® Automated Insulin Delivery compendium is a comprehensive resource for clinical news and expert insights for this technology, which has revolutionized diabetes care.
Read this review and Q&A with trial investigators of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in child and adult participants with type 1 diabetes.
September 16th 2022, 6:00pm
This randomized, multicenter study of children and adolescents with new-onset type 1 diabetes (T1D) investigated the effect on glucose control of a closed-loop system, using C-peptide levels to gauge response
September 12th 2022, 5:45pm
The review included data from 17 studies of over 400 patients using continuous glucose monitors (CGM).
September 7th 2022, 10:30pm
The trial followed patients with type 1 diabetes (T1D) for 6 months, evaluating outcomes in patients struggling to achieve glucose targets with the conventional treatment.
August 27th 2022, 6:51pm
Do-it-yourself (DIY) automated insulin delivery systems have gained rapid uptake, yielding self-reported improvements in glycemic control and quality of life for patients, but creating unique challenges for health care providers (HCPs).
August 15th 2022, 5:10pm
The interview-based study collected feedback from 16 parents of 15 youth recently diagnosed with type 1 diabetes, finding that the majority preferred a virtual continuous glucose monitoring (CGM) information initiation visit rather than an in-person visit.
August 12th 2022, 7:38pm
More efforts need to be made to remove unconscious bias when implementing approved diabetes technologies into clinical practice for all patients, said Viral Shah, MD, an endocrinologist and scientist.
August 11th 2022, 6:20pm
Compared with sensor-augmented pump therapy, closed-loop insulin delivery increased glucose time in range and reduced hypoglycemia episodes but detracted from sleep quality.
July 27th 2022, 3:00pm
Probability of continuous glucose monitoring device use was highest for patients with type 1 diabetes (T1D) in middle adulthood, decreasing as older age increased.
July 22nd 2022, 12:50pm
Children with type 1 diabetes had the highest rates of using continuous glucose monitoring and continuous subcutaneous insulin infusion in Italy, according to recent research, but economic barriers prevent widespread adoption.
July 21st 2022, 5:55pm
Patients with type 1 diabetes (T1D) who used the Omnipod 5 Automated Insulin Delivery (AID) System saw significant improvements in psychosocial outcomes, including diabetes distress and hypoglycemic confidence over a 3-month period.